US District Judge Mark Walker ruled in a class-action lawsuit that the Florida Department of Corrections must test inmates for the hepatitis C virus and provide treatment with direct-acting antivirals. The state said it is reviewing the order, which requires monthly reports starting in June.
Researchers have established an online atlas of protein signatures found at diagnosis of acute myelogenous leukemia with the goal of helping clinicians personalize treatments, according to a study in Nature Biomedical Engineering. Based on data from 205 patients and 111 cell lines, 13 protein signatures were identified based on patient outcomes.
A funding round has pulled in $50 million for EverlyWell, a diagnostics firm offering direct-to-consumer testing products. The company, which offers more than 30 in-home diagnostics tests, plans to use the money to expand its digital platform and broaden its partnerships with retailers.
Natera is launching a follow-on public offering of $100 million in shares of common stock. The offering will include a 30-day option for underwriters to purchase up to $15 million in shares at the offering price.
Qiagen has released its Therascreen FGFR Kit in the US market as a companion diagnostic for Balversa, a fibroblast growth factor receptor kinase inhibitor drug from Janssen Biotech. The test is designed to identify tumors with certain FGFR3 gene alterations, and Qiagen said using the kit "to help guide treatment decisions in urothelial cancer will address a high unmet medical need among patients."
A brain-mapping study found that children with sickle cell disease who had lower blood flow and lower oxygen in certain brain regions were more likely to have had silent cerebral infarctions. The study in the journal Blood analyzed blood flow in the brain using arterial spin labeling magnetic resonance imaging.
Mesoblast has gained the FDA's permission to file a biologics license application on a rolling basis for its allogeneic cellular therapy candidate remestemcel-L for children with steroid-refractory acute graft-versus-host disease.
On Wednesday, people around the globe will observe World Hemophilia Day, with the focus this year on diagnosis and outreach to people with bleeding disorders. A World Federation of Hemophilia campaign will include initiatives to promote awareness, training and data collection.
Stanford Medical Center researchers conducted a feasibility study using genomic sequencing and automated lab technology from Tempus and Notable Labs in an effort to develop personalized treatment options for patients with myelodysplastic syndromes who did not respond to standard care. The investigators plan to publish their research and present additional data at the annual meeting of the European Hematology Association in June.